TABLE 4.

Simpson-Angus Scale (SAS), Barnes Akathisia Scale (BAS), and Abnormal Involuntary Movement Scale (AIMS) Scores at Baseline and Endpoint in Phases 1, 2, and 3

	Phases 1 and 2: Open-Label (%)		Phase 3: Double-Blind (%)
	Citalopram Monotherapy	Risperidone Augmentation	Risperidone Augmentation	Placebo Augmentation
N	110	93	31	32
SAS
Baseline	1.2 ± 2.7	0.7 ± 1.3	0.7 ± 1.4	0.1 ± 0.4
Endpoint	0.7 ± 1.3	0.6 ± 1.3	0.6 ± 1.2	0.1 ± 0.3
t value (df)	−2.36 (df = 106)	−1.40 (df = 92)	−0.57 (df = 28)	−0.70 (df = 28)
p value	0.0201	0.1649	0.5728	0.4892
BAS
Baseline	0.3 ± 0.8	0.2 ± 0.6	0.1 ± 0.4	0.1 ± 0.3
Endpoint	0.2 ± 0.6	0.3 ± 0.8	0.1 ± 0.4	0.1 ± 0.4
t value (df)	−1.27 (df = 106)	0.33 (df = 92)	−0.33 (df = 28)	−0.57 (df = 28)
p value	0.2074	0.7439	0.7452	0.5728
AIMS
Baseline	0.7 ± 2.4	0.7 ± 2.8	0.6 ± 2.0	0.4 ± 1.8
Endpoint	0.7 ± 2.6	0.5 ± 1.8	0.3 ± 1.3	0.1 ± 0.4
t value (df)	0.19 (df = 106)	−1.37 (df = 92)	−1.00 (df = 28)	−0.87 (df = 28)
p value	0.8520	0.1737	0.3259	0.3892

Notes: Data are means ± SD. p Values were calculated from a paired t-test to determine whether the mean change from baseline differs from zero.